UK psychedelic medicines developer Beckley Psytech has said its candidate for treatment-resistant depression has enhanced the effect of standard antidepressants in a phase 2 trial. The top-line ...

In April 2024, the EMA held a virtual briefing where it announced plans to revisit the potential of psychedelic compounds DMT, LSD, mescaline, and psilocybin for mental health conditions.

Background Catastrophic errors in healthcare are rare, yet the consequences are so serious that where possible, special procedures are put in place to prevent them. As systems become safer, it becomes ...

Armochaeglobines A (1) and B (2), two indole-based cytochalasan alkaloids with new carbon skeletons, were obtained from the fungus Chaetomium globosum TW1-1, which was first isolated from the ...